Please login to the form below

Not currently logged in

Excellence in Innovation

Sponsored by

Back to Results


myPKFiT™ Mobile App

by Takeda UK

Summary of work

Takeda is a leader in haematology (bleeding disorders), with a long heritage backed by decades of real-world experience. Together with the haematology community, we are raising expectations for the future, including earlier diagnosis and more personalised patient care.

In this pursuit of personalised care, Takeda has launched myPKFiT™, a global platform, developed and regulated as two medical devices:

  • myPKFiT™ for Healthcare Professionals (web-based physician platform)
  • myPKFiT™ for Patients (mobile app).

The myPKFiT™ physician platform helps to determine the personalised dosing regimen for people living with moderate or severe haemophilia A who require clotting factor VIII (FVIII) replacement. The platform then generates a QR code which enables patients to access and activate the myPKFiT™ mobile app for their use. Once activated, the app serves as a digital logbook, making it convenient to record bleed and infusion events, and track estimated FVIII levels in ’real-time’ following a prophylactic infusion (injecting FVIII into the blood), which is one of its main innovative features.

Judges' comments

The myPKFiT mobile app demonstrated clear innovation in terms of supporting personalised treatment. There was also quick recognition from the HCP community – a clear breakthrough innovation.

Highly commended

opnMe - by Boehringer Ingelheim International GmbH
with support from infill healthcare communication

Highly commended

The What If? Accelerator - by Roche
with support from Virgo Health


Online Diagnostic Ambulance - by London Ambulance Service and Abbott plc

myPKFiT™ Mobile App - by Takeda UK

Key dates

Entry deadline 26 August 2021
Extended entry deadline 2 September 2021*
*additional fee applies
Judging Day 1 October 2021
Company of the Year Interviews 22 October 2021
PMEA Event 24 November 2021